$ 88.80
Details
The M290 antibody reacts with the α chain of αIELβ7 integrin. CD103 has a unique and fairly restricted tissue distribution. It is expressed on almost all intestinal intraepithelial lymphocytes (IEL), on dendritic epidermal T cells (DEC), on subpopulations of peripheral T cells, and on distinct subsets of fetal, neonatal, and adult thymocytes. E-cadherin is the epithelial-cell ligand for αIELβ7 integrin. The ordered expression of αIEL during thymocyte development (which occurs under the influence of the thymic epithelium), the high level of expression of αIEL on those peripheral T cells found in epithelial tissues (IEL and DEC), and the expression of CD103 on a subset of CD8 lymphocytes responding to allogeneic epithelial cells suggest that αIELβ7 integrin may have a common role in the interactions of T lymphocytes with epithelia during T-cell maturation and effector functions. CD103 is thought to play a role in allograft rejection. The M290 antibody is reported to efficiently inhibit αIELβ7-mediated adhesion in in vitro assays.
